Abballe Luana, Spinello Zaira, Antonacci Celeste, Coppola Lucia, Miele Ermanno, Catanzaro Giuseppina, Miele Evelina
Department of Pediatric Hematology/Oncology and Cellular and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Pharmaceutics. 2023 Feb 2;15(2):505. doi: 10.3390/pharmaceutics15020505.
Primary malignant brain tumors are the most common solid neoplasm in childhood. Despite recent advances, many children affected by aggressive or metastatic brain tumors still present poor prognosis, therefore the development of more effective therapies is urgent. Cancer stem cells (CSCs) have been discovered and isolated in both pediatric and adult patients with brain tumors (e.g., medulloblastoma, gliomas and ependymoma). CSCs are a small clonal population of cancer cells responsible for brain tumor initiation, maintenance and progression, displaying resistance to conventional anticancer therapies. CSCs are characterized by a specific repertoire of surface markers and intracellular specific pathways. These unique features of CSCs biology offer the opportunity to build therapeutic approaches to specifically target these cells in the complex tumor bulk. Treatment of pediatric brain tumors with classical chemotherapeutic regimen poses challenges both for tumor location and for the presence of the blood-brain barrier (BBB). Lastly, the application of chemotherapy to a developing brain is followed by long-term , especially on cognitive abilities. Novel avenues are emerging in the therapeutic panorama taking advantage of nanomedicine. In this review we will summarize nanoparticle-based approaches and the efficacy that NPs have intrinsically demonstrated and how they are also decorated by biomolecules. Furthermore, we propose novel cargoes together with recent advances in nanoparticle design/synthesis with the final aim to specifically target the insidious CSCs population in the tumor bulk.
Oncologist. 1997
Adv Drug Deliv Rev. 2013-10-10
J Neurooncol. 2005-12
Carcinogenesis. 2019-3-12
Curr Stem Cell Res Ther. 2009-12
Crit Rev Oncol Hematol. 2016-8-24
Pharmaceuticals (Basel). 2025-6-10
Nanomedicine (Lond). 2025-1
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024
Drug Deliv Transl Res. 2024-9
Bioengineering (Basel). 2023-6-25
Cancers (Basel). 2023-6-11
Tissue Eng Part C Methods. 2023-6
Children (Basel). 2022-10-25
Cancers (Basel). 2022-11-1
Bioorg Med Chem. 2022-10-15
J Control Release. 2022-10
Pharmaceutics. 2022-6-16